HUP0104655A2 - Szív-érrendszeri hatóanyagok kombinációi - Google Patents
Szív-érrendszeri hatóanyagok kombinációiInfo
- Publication number
- HUP0104655A2 HUP0104655A2 HU0104655A HUP0104655A HUP0104655A2 HU P0104655 A2 HUP0104655 A2 HU P0104655A2 HU 0104655 A HU0104655 A HU 0104655A HU P0104655 A HUP0104655 A HU P0104655A HU P0104655 A2 HUP0104655 A2 HU P0104655A2
- Authority
- HU
- Hungary
- Prior art keywords
- inhibitor
- combinations
- acid derivative
- microsomal
- cetp
- Prior art date
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 abstract 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000001906 cholesterol absorption Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940125753 fibrate Drugs 0.000 abstract 2
- 230000003228 microsomal effect Effects 0.000 abstract 2
- 239000012268 protein inhibitor Substances 0.000 abstract 2
- 229940121649 protein inhibitor Drugs 0.000 abstract 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 229940077672 Ileal bile acid transport inhibitor Drugs 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 abstract 1
- -1 cholesteryl ester Chemical class 0.000 abstract 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000002516 radical scavenger Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A tal lm ny szív-érrendszeri ter pi s vegyület kombin cióit ismertetiszív-érrendszeri betegség, ezen belül hiperkoleszterinémia ésérszűkület megelőzésére vagy kezelésére. Az ismertetett kombin ciókcsípőbél-epesav transzport inhibitort egy koleszteril észtertranszport protein (CETP) inhibitorral, fibrinsavsz rmazékkal,nikotinsavsz rmazékkal, mikroszóm s triglicerid transzfer protein-inhibitorral, koleszterinfelszívód s-antagonist val, fitoszterinnel,sztanollal, magas vérnyom s elleni szerrel vagy m s szerekkel kombinlva tartalmaznak. Tov bbi kombin ciók k"zé tartozik a CETP-inhibitorfibrinsav-sz rmazékkal, nikotinsav-sz rmazékkal, epesav-elvonószerrel, mikroszóm s triglicerid transzfer protein-inhibitorral,koleszterinfelszívód s-antagonist val vagy m s vegyületekkel képzettkombin ciói. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11395598P | 1998-12-23 | 1998-12-23 | |
PCT/US1999/027946 WO2000038725A1 (en) | 1998-12-23 | 1999-12-17 | Combinations for cardiovascular indications |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0104655A2 true HUP0104655A2 (hu) | 2002-04-29 |
Family
ID=22352512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0104655A HUP0104655A2 (hu) | 1998-12-23 | 1999-12-17 | Szív-érrendszeri hatóanyagok kombinációi |
Country Status (23)
Country | Link |
---|---|
US (1) | US20040058908A1 (hu) |
EP (2) | EP1140187B1 (hu) |
JP (1) | JP2002533411A (hu) |
KR (1) | KR20020002367A (hu) |
CN (1) | CN1342091A (hu) |
AR (1) | AR037482A1 (hu) |
AT (1) | ATE248606T1 (hu) |
AU (1) | AU779264B2 (hu) |
BR (1) | BR9916564A (hu) |
CA (1) | CA2356515A1 (hu) |
CZ (1) | CZ20012344A3 (hu) |
DE (1) | DE69911058T2 (hu) |
DK (1) | DK1140187T3 (hu) |
EA (1) | EA200100704A1 (hu) |
ES (1) | ES2207330T3 (hu) |
HU (1) | HUP0104655A2 (hu) |
IL (1) | IL143944A0 (hu) |
MX (1) | MXPA01006468A (hu) |
NO (1) | NO20013157L (hu) |
NZ (1) | NZ512532A (hu) |
PT (1) | PT1140187E (hu) |
WO (1) | WO2000038725A1 (hu) |
ZA (5) | ZA200105062B (hu) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
US6699508B1 (en) * | 1998-08-10 | 2004-03-02 | Asahi Kasei Pharma Corporation | Sustained release oral preparations of fasudil hydrochloride |
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
AU2001247331A1 (en) * | 2000-03-10 | 2001-09-24 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
AR030414A1 (es) * | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos |
US20040009961A1 (en) * | 2000-04-19 | 2004-01-15 | Borody Thomas Julius | Composition and therapies for hyperlipidaemia-associated disorders |
SE0002354D0 (sv) * | 2000-06-22 | 2000-06-22 | Astrazeneca Ab | New formulation |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
AU2006203175B2 (en) * | 2001-01-26 | 2008-07-24 | Organon Llc | Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications |
EP1671650A1 (en) * | 2001-01-26 | 2006-06-21 | Schering Corporation | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
AU2007201970B2 (en) * | 2001-01-26 | 2008-04-17 | Organon Llc | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
CN1915429B (zh) * | 2001-01-26 | 2010-12-15 | 先灵公司 | 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药 |
AU2006202618B2 (en) * | 2001-01-26 | 2007-04-19 | Organon Llc | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
DE60221798T2 (de) * | 2001-01-26 | 2008-06-05 | Schering Corp. | Kombinationen von gallensäure sequestriermitteln und hemmern der sterol absorption zur behandlung von kardiovaskulären indikationen |
BR0206654A (pt) * | 2001-01-26 | 2004-02-25 | Schering Corp | Combinações de ativador(es) de receptor ativado por proliferação de peroxisoma (ppar) e inibidor(es) de absorção de esterol e tratamentos para indicações vasculares |
EP1541175A3 (en) * | 2001-01-26 | 2006-04-12 | Schering Corporation | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
CA2439920A1 (en) * | 2001-03-08 | 2002-09-19 | Merck & Co., Inc. | Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
CN1655792A (zh) * | 2001-08-22 | 2005-08-17 | 安万特医药德国有限公司 | 1,4-苯并硫杂䓬-1,1-二氧化物衍生物与其它活性成分的组合产物及其用途 |
MXPA04001256A (es) * | 2001-08-22 | 2004-05-27 | Aventis Pharma Gmbh | Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso. |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
ATE349214T1 (de) | 2001-09-08 | 2007-01-15 | Astrazeneca Ab | Benzothiazepin und benzothiadiazepin derivative mit hemmender wirkung auf den säuretransport in den gallengängen zur behandlung von hyperlipidaemia |
CA2470931A1 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | Chalcone derivatives and their use to treat diseases |
US7202247B2 (en) | 2001-12-19 | 2007-04-10 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
WO2003061604A2 (en) * | 2002-01-17 | 2003-07-31 | Pharmacia Corporation | Novel alkyl/aryl hydroxy or keto thiepines. |
CN1642556A (zh) * | 2002-03-18 | 2005-07-20 | 法玛西雅公司 | 醛固酮受体拮抗剂与胆汁酸多价螯合剂的联合 |
CN1642573A (zh) * | 2002-03-18 | 2005-07-20 | 法玛西雅公司 | 醛固酮受体拮抗剂和贝酸衍生物的联合用药 |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US7786101B2 (en) | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
AU2002368326A1 (en) * | 2002-11-05 | 2004-06-07 | Schering Aktiengesellschaft | Hormone replacement therapy with drospirenone |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
DE602004029715D1 (de) | 2003-12-23 | 2010-12-02 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
SI1725234T1 (sl) | 2004-03-05 | 2013-04-30 | The Trustees Of The University Of Pennsylvania | Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov |
US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
US7728015B2 (en) | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
EA200601414A1 (ru) | 2004-04-22 | 2007-02-27 | Мор Рисерч Эппликейшнз Лтд. | Способ контроля потребления пищи |
EP2208496A1 (en) * | 2004-08-25 | 2010-07-21 | Essentialis, Inc. | Pharmaceutical formulations of potassium ATP channel openers and uses thereof |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
AU2006304689A1 (en) * | 2005-10-18 | 2007-04-26 | Aegerion Pharmaceuticals | Compositions for lowering serum cholesterol and/or triglycerides |
EP2332526A3 (en) | 2005-10-21 | 2011-10-12 | Novartis AG | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
US8865707B2 (en) | 2005-12-30 | 2014-10-21 | Merck Sharp & Dohme Corp. | Cholesteryl ester transfer protein inhibitors |
EP3545958B1 (en) | 2006-01-05 | 2024-07-10 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
AU2007338625A1 (en) * | 2006-12-21 | 2008-07-03 | Aegerion Pharmaceuticals, Inc. | Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor |
AU2008272923A1 (en) * | 2007-07-02 | 2009-01-08 | Essentialis, Inc. | Salts of potassium ATP channel openers and uses thereof |
US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
CN104042617A (zh) | 2009-04-29 | 2014-09-17 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
CN105287604B (zh) | 2010-11-08 | 2019-07-09 | 阿尔比里奥公司 | 含ibat抑制剂和胆汁酸结合剂的药物组合 |
CA2815749C (en) | 2010-11-08 | 2019-12-03 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
JP2012171911A (ja) | 2011-02-22 | 2012-09-10 | Kao Corp | Ppar活性化剤 |
EA201891154A1 (ru) | 2011-10-28 | 2019-02-28 | ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи | Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей |
US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
US8864587B2 (en) | 2012-10-03 | 2014-10-21 | Sony Corporation | User device position indication for security and distributed race challenges |
JP2016514684A (ja) | 2013-03-15 | 2016-05-23 | ルメナ ファーマシューティカルズ エルエルシー | 原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤 |
WO2014144485A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
US9142141B2 (en) | 2013-09-17 | 2015-09-22 | Sony Corporation | Determining exercise routes based on device determined information |
US9269119B2 (en) | 2014-01-22 | 2016-02-23 | Sony Corporation | Devices and methods for health tracking and providing information for improving health |
CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
EP3413878B1 (en) | 2016-02-09 | 2021-04-14 | Albireo AB | Oral cholestyramine formulation and use thereof |
CN108601744B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
CA3071182A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
CA3100113A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
AU2019290337B2 (en) | 2018-06-20 | 2023-01-12 | Albireo Ab | Crystal modifications of odevixibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
WO2020161216A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
JP7504109B2 (ja) | 2019-02-06 | 2024-06-21 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
JP2022519905A (ja) | 2019-02-12 | 2022-03-25 | ミルム ファーマシューティカルズ インコーポレイテッド | 胆汁酸塩排出ポンプ欠損症の患者における遺伝子型およびasbtiに対する用量依存的反応 |
CN111789843A (zh) * | 2019-04-08 | 2020-10-20 | 深圳奥萨医药有限公司 | 含氨氯地平、氯噻酮和阿米洛利的药物组合物 |
CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CN114786772B (zh) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
PE20230234A1 (es) | 2019-12-04 | 2023-02-07 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar |
AR120683A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
TW202134221A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
AR120674A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiazepina y su uso como ácido biliar |
AR120676A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
PT4069360T (pt) | 2019-12-04 | 2024-03-06 | Albireo Ab | Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar |
CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
EP4188541A1 (en) | 2020-08-03 | 2023-06-07 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症(pfic)を処置するためのオデビキシバット |
EP4255565A1 (en) | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
WO2024064630A1 (en) * | 2022-09-19 | 2024-03-28 | M2Sp Llc | Treatment for heart failure with preserved ejection fraction with guanethidine and guanadrel |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB860303A (en) * | 1958-06-20 | 1961-02-01 | Ici Ltd | Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª |
US3287370A (en) * | 1965-06-08 | 1966-11-22 | Mcneilab Inc | Tetrahydrobenzothiepins |
US3389144A (en) * | 1965-06-08 | 1968-06-18 | Mcneilab Inc | 5-pyridyl-2, 3, 4, 5-tetrahydrobenzothiepin-5-ols |
US3444176A (en) * | 1967-04-28 | 1969-05-13 | Mcneilab Inc | Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof |
US3674836A (en) * | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4058552A (en) * | 1969-01-31 | 1977-11-15 | Orchimed Sa | Esters of p-carbonylphenoxy-isobutyric acids |
FR2077733B1 (hu) * | 1970-02-10 | 1973-03-16 | Roussel Uclaf | |
US3694446A (en) * | 1970-02-24 | 1972-09-26 | William J Houlihan | 5-(substituted-benzyl)-benzocycloheptenes and-1-benzthiepines |
US3692895A (en) * | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
DE2230383C3 (de) * | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben |
US4002750A (en) * | 1972-04-28 | 1977-01-11 | Carlo Erba S.P.A. | Pyrazine 4-oxide derivatives and process for their preparation |
US3948973A (en) * | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
US3962261A (en) * | 1974-02-04 | 1976-06-08 | Warner-Lambert Company | 2,3,4,5-tetra hydro-5-oxo-1-benzothiepi n-4-carboxamide 1,1-dioxides |
FR2260569B1 (hu) * | 1974-02-08 | 1978-06-16 | Ugine Kuhlmann | |
JPS5612114B2 (hu) * | 1974-06-07 | 1981-03-18 | ||
SE420725B (sv) * | 1974-09-26 | 1981-10-26 | Ciba Geigy Ag | Sett att framstella 2,3-dihydro-1-benstiepin-4-karboxylsyraamider |
US4251526A (en) * | 1977-10-31 | 1981-02-17 | Mccall John M | 2-Benzothiepins and compositions and methods of use therefore |
US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) * | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
FI77669C (fi) * | 1983-04-13 | 1989-04-10 | Ciba Geigy Ag | 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat. |
US5158943A (en) * | 1988-11-21 | 1992-10-27 | Takeda Chemical Industries, Ltd. | Sulfur-containing heterocyclic compounds |
US5075293A (en) * | 1989-10-10 | 1991-12-24 | The Dow Chemical Company | ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides |
US5153184A (en) * | 1989-10-10 | 1992-10-06 | Dowelanco | ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides |
DE69127207T2 (de) * | 1991-05-03 | 1998-01-22 | Raision Tehtaat Oy Ab | Substanz zur absenkung eines hohen cholesterolspiegels im serum und verfahren zu ihrer herstellung |
US5350761A (en) * | 1991-07-30 | 1994-09-27 | Ciba-Geigy Corporation | Indolyl substituted hydroxylamine derivatives |
US5260316A (en) * | 1991-07-30 | 1993-11-09 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
US5334600A (en) * | 1991-07-30 | 1994-08-02 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
US5519001A (en) * | 1991-12-19 | 1996-05-21 | Southwest Foundation For Biomedical Research | CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
DK0549967T3 (da) * | 1991-12-20 | 1996-07-22 | Hoechst Ag | Polymerer og oligomerer af galdesyrederivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler |
US5244887A (en) * | 1992-02-14 | 1993-09-14 | Straub Carl D | Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof |
GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
FR2698873B1 (fr) * | 1992-12-07 | 1995-02-24 | Lipha | Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant. |
WO1994009774A1 (en) * | 1992-10-26 | 1994-05-11 | Merck & Co., Inc. | Biologically active compounds and process therefor |
IL108633A (en) * | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
TW289021B (hu) * | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
TW289020B (hu) * | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
US5703188A (en) * | 1993-06-02 | 1997-12-30 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
DE69520364T2 (de) * | 1994-09-13 | 2001-09-13 | Monsanto Company, St. Louis | Benzothepines mit wirkung als inhibitoren des gallensäuretransports und der taurocholate-aufnahme |
US5705524A (en) * | 1994-11-04 | 1998-01-06 | Gilead Sciences, Inc. | Thiepane compounds |
US6034118A (en) * | 1994-11-04 | 2000-03-07 | Gilead Sciences, Inc. | Thiepane compounds |
NZ335162A (en) * | 1996-11-27 | 2000-01-28 | Pfizer | Apo b-secretion/mtp inhibitory amides |
ES2198613T3 (es) * | 1997-03-14 | 2004-02-01 | Aventis Pharma Deutschland Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos. |
US5929062A (en) * | 1997-06-19 | 1999-07-27 | University Of Western Ontario | Oxysterol inhibition of dietary cholesterol uptake |
-
1999
- 1999-12-17 NZ NZ512532A patent/NZ512532A/en unknown
- 1999-12-17 BR BR9916564-3A patent/BR9916564A/pt not_active IP Right Cessation
- 1999-12-17 CN CN99816302A patent/CN1342091A/zh active Pending
- 1999-12-17 JP JP2000590676A patent/JP2002533411A/ja active Pending
- 1999-12-17 CZ CZ20012344A patent/CZ20012344A3/cs unknown
- 1999-12-17 CA CA002356515A patent/CA2356515A1/en not_active Abandoned
- 1999-12-17 AT AT99965901T patent/ATE248606T1/de not_active IP Right Cessation
- 1999-12-17 AU AU21577/00A patent/AU779264B2/en not_active Ceased
- 1999-12-17 DE DE69911058T patent/DE69911058T2/de not_active Expired - Fee Related
- 1999-12-17 KR KR1020017008088A patent/KR20020002367A/ko not_active Application Discontinuation
- 1999-12-17 ES ES99965901T patent/ES2207330T3/es not_active Expired - Lifetime
- 1999-12-17 EA EA200100704A patent/EA200100704A1/ru unknown
- 1999-12-17 EP EP19990965901 patent/EP1140187B1/en not_active Revoked
- 1999-12-17 WO PCT/US1999/027946 patent/WO2000038725A1/en not_active Application Discontinuation
- 1999-12-17 IL IL14394499A patent/IL143944A0/xx unknown
- 1999-12-17 HU HU0104655A patent/HUP0104655A2/hu unknown
- 1999-12-17 MX MXPA01006468A patent/MXPA01006468A/es unknown
- 1999-12-17 EP EP03016600A patent/EP1354604A1/en not_active Withdrawn
- 1999-12-17 DK DK99965901T patent/DK1140187T3/da active
- 1999-12-17 PT PT99965901T patent/PT1140187E/pt unknown
- 1999-12-23 AR ARP990106756A patent/AR037482A1/es not_active Application Discontinuation
-
2001
- 2001-06-20 ZA ZA200105062A patent/ZA200105062B/en unknown
- 2001-06-20 ZA ZA200105060A patent/ZA200105060B/en unknown
- 2001-06-20 ZA ZA200105061A patent/ZA200105061B/en unknown
- 2001-06-20 ZA ZA200105059A patent/ZA200105059B/en unknown
- 2001-06-20 ZA ZA200105056A patent/ZA200105056B/en unknown
- 2001-06-22 NO NO20013157A patent/NO20013157L/no not_active Application Discontinuation
-
2002
- 2002-10-09 US US10/266,743 patent/US20040058908A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU779264B2 (en) | 2005-01-13 |
JP2002533411A (ja) | 2002-10-08 |
NO20013157D0 (no) | 2001-06-22 |
CA2356515A1 (en) | 2000-07-06 |
NZ512532A (en) | 2003-12-19 |
CZ20012344A3 (cs) | 2002-01-16 |
EA200100704A1 (ru) | 2002-02-28 |
ES2207330T3 (es) | 2004-05-16 |
AR037482A1 (es) | 2004-11-17 |
ZA200105056B (en) | 2002-06-20 |
EP1140187B1 (en) | 2003-09-03 |
DK1140187T3 (da) | 2003-12-22 |
AU2157700A (en) | 2000-07-31 |
US20040058908A1 (en) | 2004-03-25 |
KR20020002367A (ko) | 2002-01-09 |
ZA200105059B (en) | 2002-06-20 |
ZA200105061B (en) | 2002-06-20 |
PT1140187E (pt) | 2004-01-30 |
DE69911058T2 (de) | 2004-06-03 |
DE69911058D1 (de) | 2003-10-09 |
NO20013157L (no) | 2001-08-22 |
ZA200105060B (en) | 2002-09-20 |
BR9916564A (pt) | 2002-01-29 |
EP1354604A1 (en) | 2003-10-22 |
WO2000038725A1 (en) | 2000-07-06 |
EP1140187A1 (en) | 2001-10-10 |
CN1342091A (zh) | 2002-03-27 |
ZA200105062B (en) | 2002-08-28 |
MXPA01006468A (es) | 2004-03-10 |
ATE248606T1 (de) | 2003-09-15 |
IL143944A0 (en) | 2002-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0104655A2 (hu) | Szív-érrendszeri hatóanyagok kombinációi | |
HUP0004318A2 (hu) | Atorvastatint és egy vérnyomáscsökkentő szert tartalmazó gyógyszerkészítmény | |
CA2356422A1 (en) | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications | |
PL339092A1 (en) | Therapeutic compositions containing amlodipin and atorvastatin | |
HUP0104745A2 (hu) | Csípőbél epesav transzport inhibitorok és epesav elvonószerek kombinációi szív-érrendszeri indikációkhoz | |
BRPI0206641B8 (pt) | uso de um inibidor da absorção de esteróis | |
EP0857487A3 (en) | Combinations for prophylaxsis and/or treatment of benign prostatic hyperplasia containing a 17 beta-hydroxy steroid dehydrogenase (17bHSD) inhibitor and at least one further active ingredient | |
HUP0004396A2 (hu) | A lipoprotein-oxidáció gátlására szolgáló, hatóanyagként hidroxilezett koleszterincsökkentő szert tartalmazó gyógyszerkészítmények | |
BR9916567A (pt) | Combinações de inibidores do transporte ácido dabile ileal e derivados do ácido nicotìnico paraindicações cardiovasculares | |
ATE277895T1 (de) | 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren | |
NO941679D0 (no) | Gallesyrederivater, fremgangsmåte for fremstilling og deres anvendelse | |
IL165255A0 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease | |
BR9811099A (pt) | Inibidores de urocinase | |
CA2296726A1 (en) | Combination therapy | |
DK1053239T3 (da) | Gluccocorticoid-selektive, anti-inflammatoriske midler | |
WO2001035950A3 (en) | Benzamide therapeutics and methods for treating inflammatory bowel disease | |
NZ333723A (en) | A synergistic combination of an insulin resistance improving agent and an angiotensin II receptor antagonist or an angiotensin converting enzyme inhibitor | |
WO1996028185A3 (en) | Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor | |
NO20001515L (no) | Vitronektin reseptor-antagonist | |
MY118986A (en) | Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia | |
BR9811937A (pt) | Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados | |
CA2356157A1 (en) | Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications | |
CA2055948A1 (en) | Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria | |
EP0976404A3 (en) | A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal | |
AU3299199A (en) | Compositions for inhibiting human immunodeficiency virus using hydroxyurea and areverse transcriptase inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |